# Avrion Therapeutics jobs and careers

> 0 open roles at Avrion Therapeutics as of October 23, 2026. Source: https://www.thejobsmap.com/company/avrion-therapeutics

Avrion Therapeutics is a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) developing innovative precision gene therapies for neurodegenerative disorders. Avrion’s approach is based on cell-type specific vector-based solutions to target discrete Central Nervous System (CNS) cell populations. This results in synergistic neuroprotection, while simultaneously enhancing safety. Avrion’s first gene therapy candidates target Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease (MND). Investigation of ALS pathogenic mechanisms has mostly been focused on motor neurons so far. However, emerging evidence supports that non-neuronal cells (i. e. astrocytes, microglia) play a critical role in the disease, through reshaping neuronal synaptic connections. To address this pathology, Avrion has engineered two candidate gene therapy products referred to as AVR-001 and AVR-002. The first candidate (AVR-001) harnessed an advanced vector platform designed to selectively and simultaneously target ALS associated with mutations (or pathogenic misfolding) of SOD1 in both neurons and astrocytes. AVR-001 has been validated as potently effective and safe in both rodent and non-human primate models. Our second candidate gene therapy product (AVR-002) addresses all forms of ALS. AVR-002 is designed to engage a novel neuroimmune pathophysiological mechanism which occurs in both familial and sporadic forms of ALS, plus potentially other neurodegenerative disorders (like frontotemporal dementia). This wholly novel disease mechanism emerged from a suppressor screen using our discovery platform, which exploits humanized Drosophila as disease models. The uniqueness of AVR-002 therapeutic solution is to combine (i) vector-based targeting of glial cells, and (ii) protein engineering to deliver a cell-type selective neuro-immunomodulatory factor that can protect neuronal synaptic connections in ALS.

## Key facts

| | |
|---|---|
| Open roles | 0 |
| Headquarters | Switzerland |
| Employees | 1 to 10 |
| Website | https://avriontx.com |

## Leadership

- Harald Petry, Chief Executive Officer

## Common questions

### Is Avrion Therapeutics hiring right now?

Avrion Therapeutics has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on Avrion Therapeutics's careers site.

### Where is Avrion Therapeutics headquartered?

Avrion Therapeutics is headquartered in Switzerland.

### Who leads Avrion Therapeutics?

Harald Petry, Chief Executive Officer, is at the top of Avrion Therapeutics's org chart.

### How do I apply for a job at Avrion Therapeutics?

Pick a role on Avrion Therapeutics's TheJobsMap page and select Apply. Every listing links to the original posting on Avrion Therapeutics's own careers site, so you apply directly with the employer.